TPB · Turning Point Brands, Inc.
$55.64
+0.32 (+0.58%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.24B
Shares
20.05M
Volume · Oct 2
444.03K
Avg daily vol (3M)
354.99K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$55.64
Open$55.68
Day$55.11–57.26
52W close$55.32–142.98
Avg vol 30d383K
Short int3.0M · 15.0% float · 12.1d
Short vol52%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 4 wks
filed Aug 4, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$507.23M
Trailing 12 months
Net income (TTM)
$44.55M
Trailing 12 months
Revenue growth YoY
+22.6%
Year over year
Operating margin
14.8%
Trailing 12 months
P / E (TTM)
17.9
Trailing earnings · reciprocal yield 5.6%
FCF yield
1.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.0%
Year over year · more shares
Price change (1Y)
-42.5%
Trailing year
Short interest
15.0%
Latest settlement · 12.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Turning Point Brands delivered Q2 Modern Oral gross revenue growth of 149% to $87.0 million and net sales growth of 128% to $68.4 million, now 48% of total net sales, and raised its FY2026 Modern Oral gross sales guidance to $330–$350 million and net sales guidance to $260–$270 million. However, GAAP net income fell 75.2% to $3.6 million and Adjusted EBITDA declined 50.0% to $15.2 million, reflecting heavy SG&A investment.
Bullish
- + Modern Oral net sales jumped 128% YoY to $68.4M, now 48% of total net sales
Bearish
- − Adjusted EBITDA declined 50.0% to $15.2M driven by strategic sales and marketing investments
- − SG&A surged 91.1% to $76.9M as Modern Oral-related sales and marketing investments and freight costs ramped
- − Zig-Zag segment net sales fell 24.8% YoY, weighing on the consolidated mix
- − Stoker's adjusted gross margin contracted to 56.9% from 62.5% on higher chain penetration
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
−27%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−33%
trailing
YTD return
−49%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $76 › 200d $91 — 200d above 50d
Institutional flow
Distributing
2 of 231 funds reported for Sep 30 · net -2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.03% of float · ▲ +7.8% MoM · 12.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
231 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+28%
Y/Y
Gross margin
57%
expanding
EPS growth
+45%
Y/Y
Free cash flow
$43.8M
Valuation
P/E 20
in line
Buyback
$139.2M
remaining
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Modern Oral Gross Sales
· full year 2026
Initiated
$330M – $350M
Modern Oral Net Sales
· full year 2026
Initiated
$260M – $270M
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$70M – $90M
Guided vs delivered
· last 8 settled
Net sales
2021
guided $433M – $443M
$445.47M
Beat +1.7%
Sales
fourth quarter
guided $93M – $100M
$105.28M
Beat +9.1%
Net sales
third quarter 2021
guided $109M – $114M
$109.9M
In line
Net sales
second quarter
guided $103M – $109M
$122.64M
Beat +15.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $76 › 200d $91 — 200d above 50d
Institutional flow
Distributing
2 of 231 funds reported for Sep 30 · net -2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.03% of float · ▲ +7.8% MoM · 12.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
231 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $55
Now $56 · 0%
Range high $143
vs 200-day avg -39%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Tobacco — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TPB
this stock
Turning Point Brands, Inc.
|
$1.24B | -48.7% | +28.4% | 20.0 | 15.0% |
|
PM
Philip Morris International Inc.
|
$296.88B | +16.9% | +7.3% | 27.4 | 0.9% |
|
BTI
British American Tobacco p.l.c.
|
$118.02B | -7.0% | — | — | 0.1% |
|
MO
Altria Group, Inc.
|
$114.91B | +16.8% | -3.1% | 14.5 | 2.3% |
|
RLX
RLX Technology Inc.
|
$2.05B | -26.6% | +50.3% | — | 0.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TPB | -10.4% | -27.7% | -33.2% | -5.2% | -48.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -10.1% | -27.2% | -45.3% | -6.1% | -61.5% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$200.00M
Spent (derived)
$60.80M
Remaining
$139.20M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.